Mouhamed Al Sheikha, MD
Nephrology · Davenport, IANPI 1063418374
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,214 of the $1,366 with a category attached, or 88.8%. It is spread thinly across 20 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $501, 3.9 times the $128 reported in 2019.
Across 61 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$204
- Novartis$178
- Bayer$122
- AstraZeneca$118
- Ardelyx, Inc.$93
- AbbVie$91
- plus $561 from 14 others
What the payments were for
- Food & beverage$1,21489%
- Education$15211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $204 |
| Novartis | 9 | $178 |
| Bayer | 6 | $122 |
| AstraZeneca | 7 | $118 |
| Ardelyx, Inc. | 4 | $93 |
| AbbVie | 2 | $91 |
| Novo Nordisk | 5 | $85 |
| Amgen | 4 | $70 |
| Lexicon Pharmaceuticals, Inc. | 3 | $68 |
| Baxter Healthcare | 1 | $60 |
| Travere Therapeutics, Inc. | 2 | $54 |
| Boehringer Ingelheim | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Lilly USA, LLC | 2 | $28 |
| Vifor Pharma, Inc. | 1 | $27 |
| Akebia Therapeutics Inc | 1 | $25 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Sanofi | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $15 |
How this compares
$1,366 in reported general payments places this provider in the 80th percentile of 73 nephrology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 141 | $100,640 |
| JardianceEmpagliflozin | 98 | $63,528 |
| KerendiaFinerenone | 73 | $55,686 |
| AuryxiaFerric Citrate | 13 | $40,315 |
| EliquisApixaban | 16 | $18,180 |
| JanuviaSitagliptin Phosphate | 18 | $17,053 |
| EntrestoSacubitril/Valsartan | 16 | $14,312 |
| MounjaroTirzepatide | 11 | $12,015 |
| Sevelamer Carbonate | 86 | $10,857 |
| Calcium Acetate | 155 | $10,071 |
| Lanthanum Carbonate | 15 | $7,830 |
| Nifedipine ErNifedipine | 251 | $5,340 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,914 |
| Midodrine Hcl | 73 | $4,125 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $3,301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $118 | $100,640141 claims |
| Boehringer IngelheimJardiance | $43 | $63,52898 claims |
| BayerKerendia | $122 | $55,68673 claims |
| Akebia Therapeutics IncAuryxia | $25 | $40,31513 claims |
| NovartisEntresto | $178 | $14,31216 claims |
| Lilly USA, LLCMounjaro | $28 | $12,01511 claims |
| AbbVieSynthroid | $91 | $81613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 73 nephrology providers in Iowa.
Other nephrology in Davenport
- Craig ShadurDes Moines$314K
- Andrew BlandDubuque$76K
- Lawrence HunsickerIowa City$70K
- Ashar LuqmanSioux City$56K
- Jeremy PepinCouncil Bluffs$42K
- Prem ChandranDes Moines$19K
- Lama NoureddineIowa City$7K
- Benjamin GriffinIowa City$6K
- Mony FraerIowa City$5K
- Jerold ErlandsonSioux City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.